Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomized, Double-blinded, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 as Booster Vaccination in Adults 18 Years of Age or Older

NCT05683600 is registered in ClinicalTrials.gov with Guangzhou Patronus Biotech Co., Ltd. as lead sponsor.

NCT NCT05683600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05683600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomized, Double-blinded, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 as Booster Vaccination in Adults 18 Years of Age or Older
Lead sponsor
Guangzhou Patronus Biotech Co., Ltd.
Phase
Phase 3
Overall status
Terminated
Start date
December 29, 2022
Completion date
July 12, 2023
Enrollment
3,000 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19